Insulet Corporation (BMV:PODD)
Mexico · Delayed Price · Currency is MXN | Market Cap | 188.60B -47.5% |
| Revenue (ttm) | 52.29B +31.9% |
| Net Income | 5.46B -24.7% |
| EPS | 77.33 -22.7% |
| Shares Out | n/a |
| PE Ratio | 34.55 |
| Forward PE | 23.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6 |
| Average Volume | 185 |
| Open | 4,402.00 |
| Previous Close | 6,038.64 |
| Day's Range | 4,402.00 - 4,402.00 |
| 52-Week Range | 4,402.00 - 6,170.25 |
| Beta | n/a |
| RSI | 44.69 |
| Earnings Date | May 6, 2026 |
About Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controll... [Read more]
Financial Performance
In 2025, Insulet's revenue was $2.71 billion, an increase of 30.73% compared to the previous year's $2.07 billion. Earnings were $247.10 million, a decrease of -40.93%.
Financial numbers in USD Financial StatementsNews
Insulet assumed with an Outperform at William Blair
William Blair assumed coverage of Insulet (PODD) with an Outperform rating. The firm believes the shares are pricing in a lot of investor concerns relating to it its type 2…
Insulet Transcript: AGM 2026
The meeting highlighted a decade of strong revenue growth, global expansion, and innovation in diabetes care. All board nominees were elected, executive compensation was approved, and auditors ratified. Leadership addressed shareholder concerns about stock performance and future competition.
Insulet price target lowered to $208 from $288 at BofA
BofA lowered the firm’s price target on Insulet (PODD) to $208 from $288 and keeps a Buy rating on the shares. After having hosted 34 medtech companies last week in…
Insulet Transcript: Bank of America Global Healthcare Conference 2026
Q1 saw strong U.S. and international growth, with seasonality impacting new patient starts due to insurance changes. Innovation remains central, with Omnipod 6 and a fully closed loop system for Type 2 diabetes set to drive future growth. Margin expansion and sales force investments support ongoing category penetration.
Early notable gainers among liquid option names on May 12th
Notable gainers among liquid option names this morning include Zebra Technologies (ZBRA) $250.97 +34.01, Arista Networks (ANET) $140.36 +3.93, Amphenol (APH) $125.91 +3.44, Insulet (PODD) $158.38 +4.2...
Insulet initiated with a Buy at Benchmark
Benchmark initiated coverage of Insulet (PODD) with a Buy rating and $250 price target The firm says the company aims to maintain its position as the market leader in automated…
Insulet Earnings Call Transcript: Q1 2026
Q1 2026 delivered 30% constant currency revenue growth, margin expansion, and strong new customer starts, prompting a raised full-year revenue outlook to 21%-23%. Robust U.S. and international performance, innovation launches, and disciplined execution support confidence in sustained growth and profitability.
Insulet Earnings release: Q1 2026
Insulet released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Insulet Slides: Q1 2026
Insulet has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Insulet Quarterly report: Q1 2026
Insulet has published its Q1 2026 quarterly earnings report on May 6, 2026.
Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand
Insulet raised its annual revenue growth forecast on Wednesday after reporting better-than-expected quarterly results, driven by strong demand for its tubeless insulin pumps that eliminate the need ...
Insulet Reports First Quarter 2026 Results
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet Slides: Investor presentation
Insulet has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.
Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...
Insulet Slides: Omnipod® 5 competitive clinical performance presentation
Insulet has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes
ACTON, Mass.--(BUSINESS WIRE)--Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes.
Insulet to Participate in BofA Securities 2026 Health Care Conference
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will prese...
Insulet Proxy statement: Proxy filing
Insulet filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Insulet Proxy statement: Proxy filing
Insulet filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet Appoints Mike Panos as Chief Commercial Officer
ACTON, Mass.--(BUSINESS WIRE)--Insulet Appoints Mike Panos as Chief Commercial Officer.
Insulet recalls some insulin devices in US over leakage risk
Insulet has recalled specific batches of its insulin-delivery pods in the U.S. after finding a manufacturing defect that could stop diabetic users from getting their full dose of the blood sugar-reg...
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S.
Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes
ACTON, Mass.--(BUSINESS WIRE)--Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes.